Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. (HKG:1349)

Market Cap	7.89B
Revenue (ttm)	777.75M
Net Income (ttm)	-68.49M
Shares Out	1.04B
EPS (ttm)	-0.08
PE Ratio	n/a
Forward PE	n/a
Dividend	0.07 (2.22%)
Ex-Dividend Date	n/a

Volume	944,000
Average Volume	1,563,391
Open	3.000
Previous Close	3.020
Day's Range	3.000 - 3.050
52-Week Range	2.130 - 5.290
Beta	-0.02
RSI	51.13
Earnings Date	Mar 31, 2026

About HKG:1349

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd., engages in the research, development, manufacture, and sale of bio-pharmaceutical products in the People's Republic of China. It offers genetic engineering platform drugs, including Trop2-SN38 ADC that is in Phase III clinical trials for Triple-negative breast cancer; CD30-DM1 antibody-drug conjugate (ADC), which have complected Phase I clinical trials for tumors; Trop2-BB05 ADC that is in Phase I clinical trial for tumors; DLL3-BB05 ADC, which is in phase I clinical trial for tumors; and H...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1996
• Employees: 925
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 1349

Financial Performance

In 2024, HKG:1349's revenue was 709.40 million, a decrease of -16.61% compared to the previous year's 850.73 million. Earnings were 39.73 million, a decrease of -63.42%.

Financial numbers in CNY